Allarity Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas H. Jensen
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 123 E. Tarpon Ave. Tarpon Springs FL United States of America 02139
- IPO Date
- Dec 21, 2021
- CIK
- 0001860657
- Website
- allarity.com
- Similar Companies
- Business
- Allarity Therapeutics, Inc. Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage precision medicine biotechnology company that develops novel oncology therapeutics and proprietary Drug Response Predictor (DRP®) companion diagnostics for personalized treatment of patients with difficult-to-treat cancers, including advanced recurrent ovarian cancer; its lead product candidate is stenoparib, an orally available small molecule dual inhibitor of PARP1/2 and Tankyrase enzymes that demonstrates clinical benefit in DRP®-selected patients and shows potential to overcome resistance to other PARP inhibitors while supporting combination therapies due to low myelotoxicity; the company also advances stenoparib-DRP® companion diagnostics and supports select external programs involving DRP® applications across tumor types such as breast cancer and multiple myeloma. Founded in 2004 as Medical Prognosis Institute A/S in Denmark and reorganized in 2021 into a U.S. corporation headquartered in Boston, Massachusetts, with an R&D facility in Hørsholm, Denmark, Allarity Therapeutics, Inc. operates globally with exclusive worldwide rights to stenoparib, partnered GMP manufacturing with Lonza, and targets unmet needs in oncology through patient stratification to enhance clinical success rates. Recent developments include the initiation of enrollment in a Phase 2 trial of stenoparib in advanced ovarian cancer in 2025, expansion of intellectual property with Australian patent acceptance for stenoparib-DRP®, a new non-exclusive global licensing agreement for breast cancer DRP® with an EU-based biotech partner including laboratory services revenue, development and presentation of a daratumumab-specific DRP® for multiple myeloma at AACR 2025, and the appointment of Jesper Høiland to the board in June 2025 to bolster commercialization strategy.
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO)
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders